Assembly Biosciences, Inc(ASMB)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$22.63
52-Week Range
$15.54 – $39.70
YTD
-32.94%
IV Rank (30D)
2.66
Straddle Price
$4.20
P/C Vol Ratio
0.24
Market Cap
$0.5B
Fair Value
+22.7% vs price
Confidence: 13% Alpha Score: 0.42

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 0.5% and dividend payments are stable.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.47%
Beta vs SPY1.00
Cost of Equity (CAPM)9.97% (VRP-adj)
WACC9.97%
Volatility Risk Premium+37.1pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)-10.0%
DCF Horizon10 years explicit + fade
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-3.2%
Book / Price72.7% — banking bias active (P/B is primary)
Gross Margin (TTM)100.0%
FCF Margin (TTM)-56.0%
Debt / Equity0.00
Quality Score2/6 — normal (10y DCF)
SMA 50$28.02 (Market Anchor value)
SMA 20 / Bollinger Mid$27.20
Bollinger Width / SMA20135.5% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: ABT, PFE, REGN (SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$27.68
Current Price
$22.55
Deviation
+22.7%
Forward-Return Rank LONG gates ✓
?
Horizon Expected α z Pred Blended z Rank % Active?
21d -1.8% +0.54 +0.55 58.0%
42d -3.7% +0.28 +0.43 46.2%
63d -4.0% +0.18 +0.37 44.0%
Expected α = forward-return point estimate vs SPY (e.g., +7.5% means the predictor expects this stock to outperform SPY by 7.5% over that horizon). For SHORT direction the model uses a different ranking metric (conviction-weighted deviation, not the LGBM prediction); Expected α is shown for reference. flags rows where Expected α disagrees with the FV direction — two independent signals are in conflict; conviction is low even if rank looks extreme.
Forward-Return Rank. A proprietary ensemble of a machine-learning forward-return model and a conviction-weighted fundamental score, ranked cross-sectionally each day across the S&P 500 (and broader universes on the screener). Each stock is scored at three horizons (21/42/63 trading days). "Active" = top/bottom 5% AND all risk filters pass. Backtested mean alpha vs SPY on active picks: 21d LONG +13.4%, 63d +34.9% (S&P 500, walk-forward). Past performance is not indicative of future results.
Value vs momentum conflict ⚠. The "FV direction" (long/short) comes from the fundamentals-based engine — price vs intrinsic value. The "Expected α" comes from a separate machine-learning predictor trained on ~12 features (sector, options-implied move, beta, institutional flow, etc.). Sometimes the two disagree: a stock is overvalued by fundamentals but the predictor expects it to keep outperforming (sector or momentum tailwinds). When all 3 horizons disagree, treat the direction signal as low-conviction — neither model is strongly recommending a position.
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 19.8× · 3 peers
Peer EV/EBITDA n/a 0% median 16.0× · 3 peers
Peer P/B $34.76 50% median 2.1× · 3 peers
Peer P/S $20.60 50% median 3.5× · 3 peers
Market Anchor (SMA50) $28.02 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-06-09 · updated 2026-06-09 13:30:08.206000
Info
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834)
Exchange
XNAS
Market Cap
$0.5B

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the tre…

Price History
Seasonality
MonthAvg ReturnYears of Data
Jan +0.15% 12
Feb +4.43% 12
Mar -4.63% 12
Apr +0.68% 12
May +5.54% 12
Jun +3.10% 12
Jul -3.02% 12
Aug +4.78% 12
Sep -4.11% 12
Oct +10.48% 12
Nov -3.24% 12
Dec -2.47% 12
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $27.20
SMA 50: $28.02
SMA 200: $28.98
Current: $22.55
EMA 12: $25.41
EMA 26: $26.77
MACD: -1.3542 | Signal: -0.5736
BEARISH
ADX (14): 15.43
RANGE
+DI: 21.03
−DI: 29.45
Momentum Oscillators
RSI (14): 29.71
OVERSOLD
Stoch %K: 4.33
Stoch %D: 4.47
Williams %R: -96.74
Volume & Volatility
BB Upper: $32.21
BB Lower: $22.19
NEUTRAL
OBV: 4,576,932
Vol SMA 20: 181,486
Vol ROC: -82.87%
ATR: $1.67
True Range: $1.42
HV 20: 59.0%
HV 30: 58.7%
HV 60: 52.2%

Data Summary
Data Points: 500
Last Updated: 2026-06-09T13:30:18.039000
Date Range: 2024-06-10T00:00:00 – 2026-06-08T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

Options Activity
IV Rank (30D)
2.66
IV Rank (7D)
75.66
Avg IV
95.8%
Straddle (30D)
$4.20
Straddle (7D)
$3.88
P/C Volume
0.24
Spread Scanner GPU

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Volatility Surface

Enter a ticker to render the implied volatility surface.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
1.49
Correlation (SPY)
31.7%
0.10
Ann. Volatility
57.3%
SPY Volatility
12.1%

High volatility - stock moves more than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-03-31
Diluted shares outstanding: 12,113,285 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

73 filers12,335,189 shares$344.60M value101.83% of float
# Filer Shares Value % of Total % of Float Period
1 GILEAD SCIENCES, INC. 4,505,391 $125.02M 36.28% 37.19% 2026-03-31
2 RA CAPITAL MANAGEMENT, L.P. 1,020,410 $28.32M 8.22% 8.42% 2026-03-31
3 Commodore Capital LP 1,000,000 $27.75M 8.05% 8.26% 2026-03-31
4 JANUS HENDERSON GROUP PLC 849,309 $23.48M 6.81% 7.01% 2026-03-31
5 VANGUARD GROUP INC Custodian 572,898 $19.48M 5.65% 4.73% 2025-12-31
6 Paradigm Biocapital Advisors LP 665,251 $18.46M 5.36% 5.49% 2026-03-31
7 Parkman Healthcare Partners LLC 411,227 $11.41M 3.31% 3.39% 2026-03-31
8 Point72 Asset Management, L.P. 344,105 $9.55M 2.77% 2.84% 2026-03-31
9 Blackstone Inc. 296,855 $8.24M 2.39% 2.45% 2026-03-31
10 MILLENNIUM MANAGEMENT LLC Custodian 233,650 $6.48M 1.88% 1.93% 2026-03-31
11 BlackRock, Inc. Custodian 202,743 $5.63M 1.63% 1.67% 2026-03-31
12 STEMPOINT CAPITAL LP 185,435 $5.15M 1.49% 1.53% 2026-03-31
13 B Group, Inc. 175,706 $4.88M 1.41% 1.45% 2026-03-31
14 MARSHALL WACE, LLP Custodian 163,400 $4.53M 1.32% 1.35% 2026-03-31
15 ADAGE CAPITAL PARTNERS GP, L.L.C. 161,000 $4.47M 1.30% 1.33% 2026-03-31
16 Patient Square Capital LP 136,315 $3.78M 1.10% 1.13% 2026-03-31
17 GEODE CAPITAL MANAGEMENT, LLC Custodian 132,971 $3.69M 1.07% 1.10% 2026-03-31
18 Schonfeld Strategic Advisors LLC 120,500 $3.34M 0.97% 0.99% 2026-03-31
19 Caption Management, LLC 81,841 $2.27M 0.66% 0.68% 2026-03-31
20 HighVista Strategies LLC 74,735 $2.07M 0.60% 0.62% 2026-03-31
21 Qube Research & Technologies Ltd 69,256 $1.92M 0.56% 0.57% 2026-03-31
22 STATE STREET CORP 56,689 $1.57M 0.46% 0.47% 2026-03-31
23 Seven Fleet Capital Management LP 56,147 $1.56M 0.45% 0.46% 2026-03-31
24 JPMORGAN CHASE & CO Custodian 53,962 $1.44M 0.42% 0.45% 2026-03-31
25 MONIMUS CAPITAL MANAGEMENT, LP 48,390 $1.34M 0.39% 0.40% 2026-03-31
1 filers$5.55K notional
# Filer Notional Value % of Total Period
1 SIMPLEX TRADING, LLC Custodian $5.55K 100.00% 2026-03-31
# Filer Notional Value % of Total Period
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

P/B Ratio2.3
P/S Ratio6.4
EV/EBITDA-31.5
TTM Revenue$0.1B
TTM Net Income$-0.0B
TTM EPS$-0.11
ROE-3.2%